Login to your account

Username *
Password *
Remember Me
RCT | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19.

RCT | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19.

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine   Commentaries on Twitter Interesting results in the #PANAMO trial of vilobelimab, an anti-C5a antibody, in critically ill ICU patients w/ COVID19. People on MV (n=386) randomized to […]

The post RCT | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19. appeared first on Links Medicus.

Lu 21 fois
Évaluer cet élément
(0 Votes)

About Author

Laissez un commentaire

Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.